HCWB: HCW Biologics Inc. Consensus Target
HCW Biologics Inc. (HCWB) develops innovative immune platforms for cancer therapy and the fight against cellular senescence, protecting its position with patents on protein structures. This price action, reaching 7.96, is supported by minimal political risks due to the humanitarian status of its developments within the US jurisdiction. The business relies on the creation of oncological drugs, which guarantees a prolonged product commercialization period.
Analytical breakdowns for HCW Biologics Inc. (HCWB)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Aggregate Debt to Equity HCW Biologics Inc.|HCWB - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital hcwbiologics.com|HCWB - Company Aggregate Debts|Debts to Book Capitalization HCW Biologics Inc|HCWB - Company Long-Term Debt|Company Short-Term Loans and Borrowings HCW Biologics|Quick Liquidity Indicator hcwbiologics.com
- business earnings and investment ratios data:
HCWB - Net Profit|Projected Future Earnings HCW Biologics Inc.|HCWB - Price to Earnings Ratio|Future Price to Earnings Multiple hcwbiologics.com|HCWB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio HCW Biologics Inc|HCWB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months HCW Biologics|HCWB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months hcwbiologics.com|HCWB - Net earnings per share growth this year|Earnings growth forecast for next year HCW Biologics Inc.
General company analysis:HCWB HCW Biologics, Inc.
This indicator represents the weighted average of target prices from leading investment houses, filtering out market noise to determine the asset's fundamental fair value. By analyzing the target price vector for HCW Biologics Inc. (HCWB), investors can observe the stability of the business valuation, which is shielded from geopolitical risks due to the humanitarian status of its onco-immunology developments within the US legal framework.
Competitors of HCW Biologics Inc.
ARGX (argenx.com) - Fair Value Consensus|Analyst Consensus Forecast BNTX (BioNTech)|ABVX - Consensus Target|ADMA: Consensus Target|Protagonist Corp (PTGX) - Consensus Target|IMVT: Analyst Consensus Forecast|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Fair Value Consensus ACRS (Aclaris Therapeutics, Inc)|KYTX: Analyst Consensus Forecast|Consensus Target tizianalifesciences.com|Consensus Target CABA|Consensus Target Ventyx Biosciences Inc. (VTYX)|Consensus Target THTX (Theratechnologies Inc)|AVTX (Avalo Therapeutics Inc) - Fair Value Consensus|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|agenusbio.com - Price Target Chart|Climb Bio - Analyst Consensus Forecast|Analyst Median Target zurabio.com ZURA|aTyr (ATYR) - Price Target Chart|Average Forecast Price Adagene Inc. (ADAG)|Price Target Chart ImageneBio|Price Target Chart STTK|Price Target Chart Equillium, Inc. (EQ)|CNTB - Average Forecast Price|Analyst Consensus Forecast IMUX (Immunic)|Analyst Target Range Atara Biotherapeutics, Inc.|InflaRx GmbH - Analyst Consensus Forecast|Analyst Median Target x4pharma.com XFOR|ACET: Analyst Consensus Forecast|Consensus Target Celularity|Price Target Chart INmune Bio Corp|Barinthus Biotherapeutics Corp (BRNS) - Analyst Median Target|Consensus Target KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|Analyst Median Target Enlivex Therapeutics Ltd (ENLV)|QTTB - Price Target Chart|GOVX (GeoVax Corp) - Broker Consensus Forecast|EDSA: Analyst Consensus Forecast|Consensus Target ibioinc.com|Consensus Target CARM|XTL Biopharmaceuticals Ltd (XTLB) - Analyst Median Target|Analyst Consensus Forecast BOLT|APVO (aptevotherapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast AIM (AIM ImmunoTech)|ADTX - Consensus Target|GRI: Consensus Target|XORTX Therapeutics Inc (XRTX) - Consensus Target|HIND: Analyst Consensus Forecast|REVB (Revelation Biosciences Corp) - Price Target Chart|Price Target Chart Indaptus Therapeutics|scinai.com - Forecast Levels Chart|Analyst Consensus Forecast CALI|AFMD (affimed.com) - Fair Value Consensus|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS - Price Target Chart|Fair Value Consensus ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Price Target Chart|Consensus Target TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
